Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Gan & Lee Starts US Trial of GLP Therapy for Type 2 Diabetes

publication date: Mar 11, 2022

Gan & Lee, a Beijing diabetes pharma, has started a US Phase I trial of its glucagon-like peptide-1 receptor agonist (GLP-1RA), a therapy for type 2 diabetes. GLP-1 is an incretin that stimulates insulin secretion and inhibits glucagon when blood glucose is high. The Phase I trial will determine the safety and tolerability of GZR18 in healthy volunteers and establish its pharmacokinetic (PK) profile. Gan & Lee, which developed the first domestic China biosynthetic human insulin, has launched five diabetes products in China. More details....

Stock Symbol: (SHA: 604087)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital